Bicycle Therapeutics Stock Today
| BCYC Stock | USD 11.10 0.15 1.33% |
PerformanceVery Weak
| Odds Of DistressLow
|
Bicycle Therapeutics is trading at 11.10 as of the 26th of February 2025, a 1.33 percent decrease since the beginning of the trading day. The stock's open price was 11.25. Bicycle Therapeutics has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 27th of January 2025 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of May 2019 | Category Healthcare | Classification Health Care |
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. The company has 47.55 M outstanding shares of which 4.3 M shares are currently shorted by private and institutional investors with about 11.04 trading days to cover. More on Bicycle Therapeutics
Moving against Bicycle Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Bicycle Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Lee MBA | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsBicycle Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bicycle Therapeutics' financial leverage. It provides some insight into what part of Bicycle Therapeutics' total assets is financed by creditors.
| |||||
Bicycle Therapeutics (BCYC) is traded on NASDAQ Exchange in USA. It is located in Portway Building, Cambridge, United Kingdom, CB21 6GS and employs 284 people. Bicycle Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 776.77 M. Bicycle Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 47.55 M outstanding shares of which 4.3 M shares are currently shorted by private and institutional investors with about 11.04 trading days to cover.
Bicycle Therapeutics currently holds about 372.77 M in cash with (60.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.56, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Bicycle Therapeutics Probability Of Bankruptcy
Ownership AllocationBicycle Therapeutics holds a total of 47.55 Million outstanding shares. The majority of Bicycle Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bicycle Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bicycle Therapeutics. Please pay attention to any change in the institutional holdings of Bicycle Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Bicycle Ownership Details
Bicycle Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Candriam Luxembourg S.c.a. | 2024-12-31 | 1.1 M | |
| Polar Capital Holdings Plc | 2024-09-30 | 1 M | |
| Ecor1 Capital, Llc | 2024-12-31 | 910 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 862.1 K | |
| Axa Sa | 2024-12-31 | 554 K | |
| Long Focus Capital Management, Llc | 2024-12-31 | 543.1 K | |
| Principal Financial Group Inc | 2024-12-31 | 406.5 K | |
| Bank Of America Corp | 2024-12-31 | 392.9 K | |
| Blackrock Inc | 2024-12-31 | 365.4 K | |
| Baker Bros Advisors Lp | 2024-12-31 | 10.9 M | |
| Point72 Asset Management, L.p. | 2024-12-31 | 4.6 M |
Bicycle Therapeutics Historical Income Statement
Bicycle Stock Against Markets
Bicycle Therapeutics Corporate Management
| Kevin MBA | CEO Director | Profile | |
| CBE FMedsci | NonEx CoFounder | Profile | |
| Christian Heinis | Scientific Founder | Profile | |
| Stephanie Yao | Senior Communications | Profile | |
| Alistair Milnes | Chief Officer | Profile | |
| Gillian Langford | Head Management | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bicycle Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bicycle Therapeutics. If investors know Bicycle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bicycle Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.28) | Revenue Per Share | Quarterly Revenue Growth (0.50) | Return On Assets | Return On Equity |
The market value of Bicycle Therapeutics is measured differently than its book value, which is the value of Bicycle that is recorded on the company's balance sheet. Investors also form their own opinion of Bicycle Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bicycle Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bicycle Therapeutics' market value can be influenced by many factors that don't directly affect Bicycle Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bicycle Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bicycle Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bicycle Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.